Michelle D. Hoarty

Statistics

Publications

Citations

248

H-Index

Active since

2020

Affiliations

UCB Pharma (United States)(Current)

Yale University

Michelle D. Hoarty is an author at UCB Pharma (United States) specializing in complement system, myasthenia gravis, and small-molecule complement inhibitors.

Publications per year

2020–2023

Publications

Clinical Effects of the Self-administered Subcutaneous Complement Inhibitor Zilucoplan in Patients With Moderate to Severe Generalized Myasthenia Gravis

James F. Howard, Richard J. Nowak, Gil I. Wolfe et al. · JAMA Neurology · 2020 · 193 citations · Full text

Life Sciences, Immunology, Pharmacology +17

Zilucoplan, a macrocyclic peptide inhibitor of human complement component 5, uses a dual mode of action to prevent terminal complement pathway activation

Guoqing Tang, Yalan Tang, Ketki Dhamnaskar et al. · Frontiers in Immunology · 2023 · 43 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +15

Myasthenia gravis complement activity is independent of autoantibody titer and disease severity

Miriam L. Fichtner, Michelle D. Hoarty, Douangsone D. Vadysirisack et al. · PLoS ONE · 2022 · 12 citations · Full text

Life Sciences, Immunology, Pathology +17

1–3 of 3